Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalizing septic shock treatment: Vasopressin's role under the microscope

NCT ID NCT07697144

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study looks at how the drug vasopressin affects the heart and blood flow in people with septic shock, a life-threatening condition from severe infection. Researchers want to see if different patients respond differently based on their specific heart and blood vessel status. The goal is to better understand when and how to use vasopressin for more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vasopressin
What this could lead to
If successful, this could help doctors tailor vasopressin use in septic shock, potentially improving survival and recovery.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to direct changes in care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients hospitalized in the intensive care unit for septic shock and with use of vasopressin

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years; * Hospitalized in an intensive care unit; * Presenting with septic shock according to Sepsis-3 criteria; * For whom the treating clinician wishes to initiate vasopressin as second-line therapy as part of routine care; * Undergoing hemodynamic monitoring with a PiCCO2 device (Pulsion Medical Systems, Getinge, Feldkirchen, Germany) or pulmonary artery catheterization as part of routine care. Exclusion Criteria: * Patient already receiving vasopressin; * Pregnancy; * Patient under legal protection; * Patient unwilling to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Septic shock and use of vasopressin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes insipidus toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septic shock and use of vasopressin

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH de Dieppe

    Dieppe, France

  • CHU Rennes - Site Pontchaillou

    Rennes, France

  • CHU d'Angers

    Angers, France

  • GHE, Hôpital Louis Pradel, HCL

    Lyon, France

  • GHS - Hôpital Lyon Sud, HCL

    Lyon, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • Hôpital Hautepierre, Hôpitaux Universitaires de Strasbourg

    Strasbourg, France

  • Hôpital Nord, AP-HM

    Marseille, France